Stock AnalizVaxcyte (PCVX) earnings for the quarter ended September 2026: EPS beats estimates
Vaxcyte reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at -$1.99 against the analysts’ average forecast of -$2.11, a beat of 5.7%.
The market’s verdict: the stock rose 1.8% on the first trading day after the report.
The last four quarters
Vaxcyte has beaten the analysts’ EPS forecast in 1 of the last 1 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$1.99 | -$2.11 | +5.7% | — | +1.8% |
What comes next
Analysts expect EPS of -$1.91 for the next quarter on average and -$7.86 for the fiscal year ending December 31, 2026.
The average analyst price target is $116.40, 84% above the current price of $63.37.
Valuation and score
Vaxcyte scores 0.4 out of 5 overall on Stock Analiz (weak). Full Vaxcyte analysis with 10 years of financials
Frequently asked questions
What was Vaxcyte’s EPS for the quarter ended September 2026?
-$1.99 adjusted per share, against an analyst consensus of -$2.11.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.